|
1
|
Stewart B and Wild CP: World Cancer Report
2014. WORLD. 2015.
|
|
2
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel
Members: Tailoring therapies--improving the management of early
breast cancer: St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopez L, Carvajal C, Gallardo M and Russo
N: Evolution in breast cancer suspicion and extent of surgery at a
radio-oncology center. Rev Chil Cir. 66:241–244. 2014.
|
|
4
|
Ross JS, Fletcher JA, Bloom KJ, Linette
GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted
therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell
Proteomics. 3:379–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ellis MJ, Coop A, Singh B, Mauriac L,
Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady
C, et al: Letrozole is more effective neoadjuvant endocrine therapy
than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen
receptor-positive primary breast cancer: Evidence from a phase III
randomized trial. J Clin Oncol. 19:3808–3816. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jordan VC: Tamoxifen (ICI46,474) as a
targeted therapy to treat and prevent breast cancer. Br J
Pharmacol. 147(Suppl 1): S269–S276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
LaVallee TM, Alvarado D, Garton AJ,
Trombetta ES, Gedrich R and McMahon G: Emerging receptor tyrosine
kinase drug targets: Implications for antibody-based therapies for
oncology and immunologic disorders. Crit Rev Oncog. 20:485–508.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kadivar A, Kamalidehghan B, Javar HA,
Davoudi ET, Zaharuddin ND, Sabeti B, Chung LY and Noordin MI:
Formulation and in vitro, in vivo evaluation of effervescent
floating sustained-release imatinib mesylate tablet. PLoS One.
10:e01268742015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manley PW, Cowan-Jacob SW, Buchdunger E,
Fabbro D, Fendrich G, Furet P, Meyer T and Zimmermann J: Imatinib:
A selective tyrosine kinase inhibitor. Eur J Cancer. 38(Suppl 5):
S19–S27. 2002. View Article : Google Scholar
|
|
11
|
Radford IR: Imatinib. Novartis Curr Opin
Investig Drugs. 3:492–499. 2002.
|
|
12
|
Buchdunger E, Cioffi CL, Law N, Stover D,
Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase
inhibitor STI571 inhibits in vitro signal transduction mediated by
c-kit and platelet-derived growth factor receptors. J Pharmacol Exp
Ther. 295:139–145. 2000.PubMed/NCBI
|
|
13
|
Malavaki CJ, Roussidis AE, Gialeli C,
Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN and Karamanos
NK: Imatinib as a key inhibitor of the platelet-derived growth
factor receptor mediated expression of cell surface heparan sulfate
proteoglycans and functional properties of breast cancer cells.
FEBS J. 280:2477–2489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang
X, Zhang W, Jin H, Su J, Jiang T, et al: Long-term exposure to
imatinib reduced cancer stem cell ability through induction of cell
differentiation via activation of MAPK signaling in glioblastoma
cells. Mol Cell Biochem. 370:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verweij J, van Oosterom A, Blay J-Y,
Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A,
Hogendoorn PC, di Paola ED, et al: Imatinib mesylate (STI-571
Glivec, Gleevec) is an active agent for gastrointestinal stromal
tumours, but does not yield responses in other soft-tissue sarcomas
that are unselected for a molecular target. Results from an EORTC
Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer.
39:2006–2011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paschka P, Marcucci G, Ruppert AS, Mrózek
K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW,
Carroll AJ, et al Cancer and Leukemia Group B: Adverse prognostic
significance of KIT mutations in adult acute myeloid leukemia with
inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin
Oncol. 24:3904–3911. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heinrich MC, Griffith DJ, Druker BJ, Wait
CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine
kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood. 96:925–932. 2000.PubMed/NCBI
|
|
18
|
Weigel MT, Meinhold-Heerlein I,
Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N and Mundhenke C:
Combination of imatinib and vinorelbine enhances cell growth
inhibition in breast cancer cells via PDGFR β signalling. Cancer
Lett. 273:70–79. 2009. View Article : Google Scholar
|
|
19
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bond M, Bernstein ML, Pappo A, Schultz KR,
Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib
mesylate in children with refractory or relapsed solid tumors: A
Children's Oncology Group study. Pediatr Blood Cancer. 50:254–258.
2008. View Article : Google Scholar
|
|
21
|
Matei D, Chang DD and Jeng M-H: Imatinib
mesylate (Gleevec) inhibits ovarian cancer cell growth through a
mechanism dependent on platelet-derived growth factor receptor α
and Akt inactivation. Clin Cancer Res. 10:681–690. 2004. View Article : Google Scholar
|
|
22
|
Gross DJ, Munter G, Bitan M, Siegal T,
Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A,
et al Israel Glivec in Solid Tumors Study Group: The role of
imatinib mesylate (Glivec) for treatment of patients with malignant
endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer.
13:535–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Jong JS, van Diest PJ, van der Valk P
and Baak JP: Expression of growth factors, growth inhibiting
factors, and their receptors in invasive breast cancer. I: An
inventory in search of autocrine and paracrine loops. J Pathol.
184:44–52. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lopes LF and Bacchi CE: Imatinib treatment
for gastrointestinal stromal tumour (GIST). J Cell Mol Med.
14:42–50. 2010. View Article : Google Scholar
|
|
25
|
Kim KB, Eton O, Davis DW, Frazier ML,
McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH,
Ross MI, et al: Phase II trial of imatinib mesylate in patients
with metastatic melanoma. Br J Cancer. 99:734–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rutkowski P, Van Glabbeke M, Rankin CJ,
Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R,
Lopez-Terrada D, et al European Organisation for Research and
Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest
Oncology Group: Imatinib mesylate in advanced dermatofibrosarcoma
protuberans: Pooled analysis of two phase II clinical trials. J
Clin Oncol. 28:1772–1779. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mahata S, Maru S, Shukla S, Pandey A,
Mugesh G, Das BC and Bharti AC: Anticancer property of Bryophyllum
pinnata (Lam.) Oken leaf on human cervical cancer cells. BMC
Complement Altern Med. 12:152012. View Article : Google Scholar
|
|
28
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Hu S, Franke RM, Filipski KK, Hu C, Orwick
SJ, de Bruijn EA, Burger H, Baker SD and Sparreboom A: Interaction
of imatinib with human organic ion carriers. Clin Cancer Res.
14:3141–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beppu K, Jaboine J, Merchant MS, Mackall
CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma
tumorigenesis and vascular endothelial growth factor expression. J
Natl Cancer Inst. 96:46–55. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin S, Shen JN, Wang J, Huang G and Zhou
JG: Oridonin induced apoptosis through Akt and MAPKs signaling
pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Uziel O, Fenig E, Nordenberg J, Beery E,
Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R,
Luria D, et al: Imatinib mesylate (Gleevec) downregulates
telomerase activity and inhibits proliferation in
telomerase-expressing cell lines. Br J Cancer. 92:1881–1891. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peng B, Lloyd P and Schran H: Clinical
pharmacokinetics of imatinib. Clin Pharmacokinet. 44:879–894. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heldin CH: Targeting the PDGF signaling
pathway in tumor treatment. Cell Commun Signal. 11:972013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsimberidou AM, Kurzrock R and Anderson
KC: The role of angiogenesis in cancer. Target Ther Transl Cancer
Res. 5:642015.
|
|
37
|
Kofler S, Nickel T and Weis M: Role of
cytokines in cardiovascular diseases: A focus on endothelial
responses to inflammation. Clin Sci (Lond). 108:205–213. 2005.
View Article : Google Scholar
|
|
38
|
Vrekoussis T, Stathopoulos EN, Kafousi M,
Navrozoglou I and Zoras O: Expression of endothelial PDGF receptors
α and β in breast cancer: Up-regulation of endothelial PDGF
receptor β. Oncol Rep. 17:1115–1119. 2007.PubMed/NCBI
|
|
39
|
Nazarenko I, Hede S-M, He X, Hedrén A,
Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in
glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wilczynski SP, Chen Y-Y, Chen W, Howell
SB, Shively JE and Alberts DS: Expression and mutational analysis
of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in
ovarian cancers. Hum Pathol. 36:242–249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jechlinger M, Sommer A, Moriggl R, Seither
P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and
Grünert S: Autocrine PDGFR signaling promotes mammary cancer
metastasis. J Clin Invest. 116:1561–1570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Geng L, Shinohara ET, Kim D, Tan J, Osusky
K, Shyr Y and Hallahan DE: STI571 (Gleevec) improves tumor growth
delay and survival in irradiated mouse models of glioblastoma. Int
J Radiat Oncol Biol Phys. 64:263–271. 2006. View Article : Google Scholar
|
|
43
|
Board R and Jayson GC: Platelet-derived
growth factor receptor (PDGFR): A target for anticancer
therapeutics. Drug Resist Updat. 8:75–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
